Trial Profile
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Epilepsy; Seizures
- Focus Adverse reactions; Registrational
- Acronyms LTFU
- Sponsors UCB
- 01 Oct 2021 The maximum permitted dose was initially 150 mg/day after protocol amendment it was increased to a maximum dose of 200 mg/day to align with other LTFU trials as per results published in the Epilepsy Research
- 05 Dec 2017 Results (n=50) assessing the safety and tolerability of long-term brivaracetam monotherapy in patients with focal seizures, presented at the 71st Annual Meeting of the American Epilepsy Society.
- 12 Apr 2017 Status changed from active, no longer recruiting to completed.